Welcome to LookChem.com Sign In|Join Free

CAS

  • or

100324-81-0

Post Buying Request

100324-81-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

100324-81-0 Usage

Chemical Properties

White Solid

Uses

Different sources of media describe the Uses of 100324-81-0 differently. You can refer to the following data:
1. A major metabolite of Pentoxifylline. Methylxanthine that inhibits production of phosphatidic acid during the inflammatory response. Immunomodulator.
2. A major metabolite of Pentoxifylline. Methylxanthine that inhibits production of phosphatidic acid during the inflammatory response. Immunomodulator

Brand name

ProTec (Cell Therapeutics).

Biological Activity

lisofylline (lsf) is a potent anti-inflammatory agent. lsf is a chiral metabolite of pentoxifylline. (r)-lsf is the biologically active isomer of lsf [1].in vitro: lisofylline preserved β-cell insulin secretion and inhibited dna damage of islets in the presence of il-1β [2]. simultaneous application of lsf and cytokines to ins-1 cells restored insulin secretion, mitochondrial membrane potential, mtt metabolism, and cell viability to control levels. lsf increased β-cell mtt metabolism as well as insulin release and glucose responsiveness [3].

in vivo

in rats subjected to hemorrhagic shock and resuscitation, lsf increased the intestinal and hepatic blood flow. treatment with lsf (15 mg/kg) ameliorated the development of mucosal damage and hyperpermeability. rats treated with lsf showed lower plasma concentrations of the intracellular hepatic enzyme, aspartate aminotransferase. lsf treatment increased concentrations of adenosine triphosphate in intestinal and hepatic tissue [1]. in nod mice, lisofylline suppressed ifn-γ production, reduced the onset of insulitis and diabetes, and inhibited diabetes after transfer of splenocytes from lisofylline-treated donors to nod.scid recipients [2].

references

[1] wattanasirichaigoon s, menconi m j, fink m p. lisofylline ameliorates intestinal and hepatic injury induced by hemorrhage and resuscitation in rats[j]. critical care medicine, 2000, 28(5): 1540-1549.[2] yang z d, chen m, wu r, et al. the anti-inflammatory compound lisofylline prevents type i diabetes in non-obese diabetic mice[j]. diabetologia, 2002, 45(9): 1307-1314.[3] chen m, yang z, wu r, et al. lisofylline, a novel antiinflammatory agent, protects pancreatic β-cells from proinflammatory cytokine damage by promoting mitochondrial metabolism[j]. endocrinology, 2002, 143(6): 2341-2348.

Check Digit Verification of cas no

The CAS Registry Mumber 100324-81-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,0,3,2 and 4 respectively; the second part has 2 digits, 8 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 100324-81:
(8*1)+(7*0)+(6*0)+(5*3)+(4*2)+(3*4)+(2*8)+(1*1)=60
60 % 10 = 0
So 100324-81-0 is a valid CAS Registry Number.
InChI:InChI=1/C13H20N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8-9,18H,4-7H2,1-3H3/t9-/m1/s1

100324-81-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 11, 2017

Revision Date: Aug 11, 2017

1.Identification

1.1 GHS Product identifier

Product name 1-[(5R)-5-hydroxyhexyl]-3,7-dimethylpurine-2,6-dione

1.2 Other means of identification

Product number -
Other names Lisophylline

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:100324-81-0 SDS

100324-81-0Relevant articles and documents

Boron-Catalyzed Regioselective Deoxygenation of Terminal 1,2-Diols to 2-Alkanols Enabled by the Strategic Formation of a Cyclic Siloxane Intermediate

Drosos, Nikolaos,Morandi, Bill

, p. 8814 - 8818 (2015)

The selective deoxygenation of polyols is a frontier in our ability to harness the stereochemical and structural complexity of natural and synthetic feedstocks. Herein, we describe a highly active and selective boron-based catalytic system for the selective deoxygenation of terminal 1,2-diols at the primary position, a process that is enabled by the transient formation of a cyclic siloxane. The method provides an ideal complement to well-known catalytic asymmetric reactions to prepare synthetically challenging chiral 2-alkanols in nearly perfect enantiomeric excess, as illustrated in a short synthesis of the anti-inflammatory drug (R)-lisofylline. Pick the right one! A highly active and selective boron-based catalytic system enables the selective deoxygenation of terminal 1,2-diols at the primary position via the transient formation of a cyclic siloxane. The utility of this method for the preparation of synthetically challenging chiral 2-alkanols was illustrated by a short synthesis of the anti-inflammatory drug (R)-lisofylline.

Chemoenzymatic enantioselective and stereo-convergent syntheses of lisofylline enantiomers via lipase-catalyzed kinetic resolution and optical inversion approach

Borowiecki, Pawe?,Zdun, Beata,Dranka, Maciej

, (2021/02/27)

Highly enantioselective enzymatic kinetic resolution (EKR) of racemic lisofylline is presented for the first time. A comprehensive optimization of the key parameters of lipase-catalyzed transesterification of racemic lisofylline revealed that optimal biocatalytic system consisted of immobilized lipase type B from Candida antarctica (Chirazyme L-2, C-3) suspended in a mixture of 3 equiv of vinyl acetate as an acetyl donor and ethyl acetate as a solvent. Under optimal reaction conditions, the 1 g-scale (Chirazyme L-2, C-3)-catalyzed kinetic resolution of racemic lisofylline furnished both the EKR products in a homochiral form (>99 % ee) with the 50 % conv., and the highest possible enantioselectivity. The best results in terms of the reaction yields (47–50 %) and enantiomeric purity of the kinetically-resolved optically active products were achieved when the preparative-scale EKR was carried out for 2 h at 60 °C. In addition, stereoinversion of the less biologically-relevant (S)-lisofylline into its (R)-enantiomer was successfully achieved via acetolysis of the respective optically pure (S)-mesylate by using 2 equiv of ceasium acetate and catalytic amount of 18-Crown-6 in dry toluene, followed by K2CO3-mediated methanolysis of (R)-acetate. The elaborated EKR methodology together with enantioconvergent strategy provided a useful chemoenzymatic protocol for the synthesis of complementary enantiomers of titled API. Moreover, we report on the first single-crystal X-ray diffraction (XRD) analyses performed for the synthesized lisofylline enantiomers. Insight into the source of CAL-B stereoselectivity toward racemic lisofylline was gained by molecular docking experiments. In silico theoretical predictions matched very well with experimental results.

Role of Chain Length and Degree of Unsaturation of Fatty Acids in the Physicochemical and Pharmacological Behavior of Drug-Fatty Acid Conjugates in Diabetes

Chitkara, Deepak,Italiya, Kishan S.,Mittal, Anupama,Narisepalli, Saibhargav,Singh, Arihant Kumar

, p. 14217 - 14229 (2021/10/20)

Several drug-fatty acid (FA) prodrugs have been reported to exhibit desirable physicochemical and pharmacological profile; however, comparative beneficial effects rendered by different FAs have not been explored. In the present study, four different FAs (linoleic acid, oleic acid, palmitic acid, and α-lipoic acid) were selected based on their chain length and degree of unsaturation and conjugated to Lisofylline (LSF), an antidiabetic molecule to obtain different drug-FA prodrugs and characterized for molecular weight, hydrophobicity, purity, self-assembly, and efficacy in vitro and in vivo in type 1 diabetes model. Prodrugs demonstrated a 2- to 6-fold increase in the plasma half-life of LSF. Diabetic animals treated with prodrugs, once daily for 5 weeks, maintained a steady fasting blood glucose level with a significant increase in insulin level, considerable restoration of biochemical parameters, and preserved β-cells integrity. Among the different LSF-FA prodrugs, LSF-OA and LSF-PA demonstrated the most favorable physicochemical, systemic pharmacokinetic, and pharmacodynamic profiles.

Efficient Transfer Hydrogenation of Ketones using Methanol as Liquid Organic Hydrogen Carrier

Garg, Nidhi,Paira, Soumen,Sundararaju, Basker

, p. 3472 - 3476 (2020/05/29)

Herein, we demonstrate an efficient protocol for transfer hydrogenation of ketones using methanol as practical and useful liquid organic hydrogen carrier (LOHC) under Ir(III) catalysis. Various ketones, including electron-rich/electron-poor aromatic ketones, heteroaromatic and aliphatic ketones, have been efficiently reduced into their corresponding alcohols. Chemoselective reduction of ketones was established in the presence of various other reducible functional groups under mild conditions.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 100324-81-0